Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mahamaya Lifesciences's ROE % for the quarter that ended in Mar. 2026 was 19.04%. Mahamaya Lifesciences's PB Ratio for the quarter that ended in Mar. 2026 was 2.89.
Mahamaya Lifesciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 6.59%.
Mahamaya Lifesciences ROE % Adjusted to Book Value Related Terms
Mahamaya Lifesciences ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Mahamaya Lifesciences's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mahamaya Lifesciences ROE % Adjusted to Book Value Chart
BOM:544611 vs CTVA, CF, MOS: ROE % Adjusted to Book Value Comparison
For the Agricultural Inputs subindustry, Mahamaya Lifesciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mahamaya Lifesciences ROE % Adjusted to Book Value vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Mahamaya Lifesciences's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Mahamaya Lifesciences's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 6.59% mean?
Mahamaya Lifesciences (BOM:544611) has a ROE % Adjusted to Book Value of 6.59% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Mahamaya Lifesciences and its competitors.
Is Mahamaya Lifesciences' ROE % Adjusted to Book Value too high?
Mahamaya Lifesciences' current ROE % Adjusted to Book Value is 6.59%. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' ROE % Adjusted to Book Value compare to CTVA and CF?
Mahamaya Lifesciences' ROE % Adjusted to Book Value of 6.59% can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for an Agriculture company?
A good ROE % Adjusted to Book Value depends on the Agriculture industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Mahamaya Lifesciences and its competitors. Mahamaya Lifesciences's current ROE % Adjusted to Book Value is 6.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current ROE % Adjusted to Book Value of 6.59%. The current ROE % Adjusted to Book Value is 6.59%. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current ROE % Adjusted to Book Value is 6.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score
Get the complete analysis for BOM:544611
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544611 has been successfully added to your 
